T1	Participants 225 288	patients with metastatic colorectal cancer (mCRC) for treatment
T2	Participants 461 609	17 polymorphisms in genes encoding drug targets, pathway molecules and detoxification enzymes was analyzed in 279 previously untreated mCRC patients
